MX365283B - Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical. - Google Patents

Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical.

Info

Publication number
MX365283B
MX365283B MX2017014577A MX2017014577A MX365283B MX 365283 B MX365283 B MX 365283B MX 2017014577 A MX2017014577 A MX 2017014577A MX 2017014577 A MX2017014577 A MX 2017014577A MX 365283 B MX365283 B MX 365283B
Authority
MX
Mexico
Prior art keywords
cathecolaminergic
neurotransmission
cortical
modulators
derivatives useful
Prior art date
Application number
MX2017014577A
Other languages
English (en)
Other versions
MX2017014577A (es
Inventor
Sonesson Clas
Pettersson Fredrik
Original Assignee
Integrative Res Laboratories Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Res Laboratories Sweden Ab filed Critical Integrative Res Laboratories Sweden Ab
Publication of MX2017014577A publication Critical patent/MX2017014577A/es
Publication of MX365283B publication Critical patent/MX365283B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente exposición se relaciona con ciertos compuestos novedosos de la Formula (I) y su utilidad en la modulación de niveles de monoaminas, dopamina, norepinefrina y serotonina en zonas corticales del cerebro y más específicamente para el tratamiento de trastornos del sistema nervioso central.
MX2017014577A 2015-05-20 2016-05-20 Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical. MX365283B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15168373 2015-05-20
SE1650485 2016-04-11
PCT/EP2016/061479 WO2016185032A1 (en) 2015-05-20 2016-05-20 Novel azetidine derivatives useful as modulators of cortical cathecolaminergic neurotransmission

Publications (2)

Publication Number Publication Date
MX2017014577A MX2017014577A (es) 2018-06-11
MX365283B true MX365283B (es) 2019-05-29

Family

ID=56026881

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014577A MX365283B (es) 2015-05-20 2016-05-20 Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical.

Country Status (18)

Country Link
US (2) US10087142B2 (es)
EP (1) EP3297987B1 (es)
JP (1) JP6679621B2 (es)
KR (1) KR102595892B1 (es)
CN (1) CN107646031B (es)
AU (1) AU2016263510B2 (es)
CA (1) CA2985710C (es)
DK (1) DK3297987T3 (es)
ES (1) ES2730890T3 (es)
HK (1) HK1245251B (es)
IL (1) IL255618B (es)
MX (1) MX365283B (es)
NZ (1) NZ737451A (es)
PL (1) PL3297987T3 (es)
PT (1) PT3297987T (es)
RU (1) RU2716814C2 (es)
WO (1) WO2016185032A1 (es)
ZA (1) ZA201707936B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107646031B (zh) * 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物
US10875829B1 (en) 2016-11-18 2020-12-29 Integrative Research Laboratories Sweden Ab Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1512969A1 (ru) * 1988-02-01 1989-10-07 Институт нефтехимического синтеза им.А.В.Топчиева Способ получени N-алкилазетидинов
FR2805818B1 (fr) * 2000-03-03 2002-04-26 Aventis Pharma Sa Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2690091A1 (en) * 2007-06-05 2008-12-11 Nsab, Filial Af Neurosearch Sweden Ab, Sverige New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
CN102224136B (zh) * 2008-11-24 2014-01-22 Nsab神经研究瑞典公司分公司 用作皮质儿茶酚胺能神经传递调节剂的3-苯基-3-甲氧基-吡咯烷衍生物
US8586572B2 (en) * 2008-11-24 2013-11-19 Integrative Research Laboratories Sweden Ab 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
US20110257148A1 (en) * 2008-11-24 2011-10-20 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
KR101273566B1 (ko) 2011-09-05 2013-06-11 한국과학기술연구원 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
CN107646031B (zh) * 2015-05-20 2020-11-17 综合研究实验室瑞典股份公司 用作皮质儿茶酚胺能神经传递调节剂的氮杂环丁烷衍生物

Also Published As

Publication number Publication date
PT3297987T (pt) 2019-06-19
CN107646031B (zh) 2020-11-17
EP3297987B1 (en) 2019-05-15
ZA201707936B (en) 2020-01-29
MX2017014577A (es) 2018-06-11
US20180141903A1 (en) 2018-05-24
IL255618B (en) 2020-02-27
JP2018520100A (ja) 2018-07-26
RU2017140419A (ru) 2019-06-20
CN107646031A (zh) 2018-01-30
NZ737451A (en) 2022-01-28
US20190031606A1 (en) 2019-01-31
US10287247B2 (en) 2019-05-14
ES2730890T3 (es) 2019-11-13
AU2016263510A1 (en) 2017-12-07
RU2716814C2 (ru) 2020-03-17
CA2985710C (en) 2023-07-25
WO2016185032A1 (en) 2016-11-24
RU2017140419A3 (es) 2019-07-26
IL255618A (en) 2018-01-31
DK3297987T3 (da) 2019-06-17
CA2985710A1 (en) 2016-11-24
AU2016263510B2 (en) 2020-03-12
US10087142B2 (en) 2018-10-02
HK1245251B (zh) 2020-04-24
KR102595892B1 (ko) 2023-10-31
PL3297987T3 (pl) 2019-10-31
JP6679621B2 (ja) 2020-04-15
EP3297987A1 (en) 2018-03-28
KR20180004742A (ko) 2018-01-12

Similar Documents

Publication Publication Date Title
CR20210335A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina
MX2009012787A (es) Nuevas fenilpirrolidinas disustituidas como moduladores de neurotransmision catecolaminergica cortical.
JOP20170067B1 (ar) معدِّلات مختلفة الشكل الفراغي لمستقبلات أسيتيل كولين النيكوتينية
PH12015500551A1 (en) Tricyclic quinoline and quinoline derivatives
MX368833B (es) Derivados de quinolina y quinazolina amidas como inhibidores de canales de sodio nav1.8 y el uso de los mismos en el tratamiento del dolor.
UY32967A (es) Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina
PH12014501963A1 (en) Inhibitors of beta-secretase
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
EA201890245A1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
MD20150071A2 (ro) Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
PH12020550472A1 (en) Substituted imidazopyridine amides and use thereof
MX2015002570A (es) Inhibidores de la beta-secretasa.
UA104152C2 (ru) Производные 3-фенил-3-метоксипирролидина, как модуляторы кортикальной катехоламинергической нейротрансмиссии
TW201613884A (en) Selective NR2B antagonists
MY192609A (en) Substituted bicyclic heteroaryl compounds as rxr agonists
MX365283B (es) Derivados de azetidina novedosos útiles como moduladores de neurotransmisión catecolaminérgica cortical.
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
GB201209015D0 (en) Novel compounds
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
MX2009012716A (es) Nuevas fenilpirrolidinas disustituidas como moduladores de la neurotransmision catecolaminergica cortical.
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.

Legal Events

Date Code Title Description
FG Grant or registration